Latest 5 articles from heartwire
- Sen Grassley questions top medical schools about ghostwriting
Nov 20, 2009 13:15 EDT - Stroke incidence related to PCI steady over 15 years
Nov 20, 2009 13:00 EDT - ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment
Nov 19, 2009 14:00 EDT - Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI
Nov 19, 2009 11:00 EDT - EFFECT: Public reporting of hospital performance improves quality of care?
Nov 19, 2009 10:00 EDT
Low-dose aspirin for primary prevention
Posted Jun 17, 2009
at 02:03 PM, EDT
by Eric Topol
A new meta-analysis questions the use of low-dose aspirin for the prevention of cardiovascular events. Given its current wide use, these findings are important and have far-reaching consequences. What are your thoughts?
See:
Meta-analysis questions use of aspirin in primary prevention
Previous postsBillets précédents
Ezetimibe in ARBITER 6-HALTS: What lessons can we learn?
No commentsAucun commentaire |
Posted Nov 16, 2009
at 05:00 PM, EDT by Eric Publié le 11.16.2009 à 17h00 par Eric
at 05:00 PM, EDT by Eric Publié le 11.16.2009 à 17h00 par Eric
Dabigatran: Crossing a remarkable threshold
No commentsAucun commentaire |
Posted Oct 14, 2009
at 11:00 AM, EDT by Eric Publié le 10.14.2009 à 11h00 par Eric
at 11:00 AM, EDT by Eric Publié le 10.14.2009 à 11h00 par Eric
Antiplatelet therapy: A step forward with individualized medicine
5 comments5 commentaires |
Posted Sep 22, 2009
at 10:30 AM, EDT by Eric Publié le 09.22.2009 à 10h30 par Eric
at 10:30 AM, EDT by Eric Publié le 09.22.2009 à 10h30 par Eric
Cash for clunkers, cash for lowering obesity rates
4 comments4 commentaires |
Posted Aug 24, 2009
at 01:50 PM, EDT by Eric Publié le 08.24.2009 à 13h50 par Eric
at 01:50 PM, EDT by Eric Publié le 08.24.2009 à 13h50 par Eric
Preventing rehospitalization for heart failure
3 comments3 commentaires |
Posted Jul 28, 2009
at 01:25 PM, EDT by Eric Publié le 07.28.2009 à 13h25 par Eric
at 01:25 PM, EDT by Eric Publié le 07.28.2009 à 13h25 par Eric
Also from theheart.org
Blogs I read
Who's talking
|
Eric J Topol MD
Director, Scripps Translational Science Institute The Gary and Mary West Chair of Innovative Medicine Chief Academic Officer, Scripps Health La Jolla, CA |














CommentsCommentaires
Aloha!
What recommendations would you recommend?
As a non-academic clinical physician, are there objective findings, on physical exam, or lab tests which i might be able to utilize which would allow me to make the most prudent recommendation?
Mahalo for your video presentation.
Madhup Joshi, MD
Dear Doctor,
It was nice to hear your vidio.I am a retired Cardiac nethesiologist and keen to get in touch the latest about CVD prevention and managements.
Have a good day.
Dr K S Johar,MBBS,MD
Any therapy is associated with risk.
Low dose aspirin for prevention of heart events in patients with atherosclerosis is clearly of value as the risk of death from MI is much greater than risk of death from bleeding.
Low dose aspirin in subjects with no atherosclerosis is unlikely to have any value in preventing a heart attack because the individual is at such low risk. The small possibility of a major bleeding event overshadows the immeasurably small risk of MI in atherosclerotisis free individuals.
I see this as yet another in a very long line of reasons that we should be doing atherosclerosis imaging. The presence of any calcium within coronary vessels increases one's risk of an MI by 3 times that risk predicted by conventional risk factors (MESA), a score >100 increases risk 7 times. This should be a clear indication for low dose aspirin (plus other medical and lifestyle interventions).
The absence of calcium in coronary vessels by EBT is associated with a 10 year risk of 1%. With this level of risk, aspirin can only cause harm as you would need to put 3,000 subjects on ASA for ten years to maybe prevent one heart attack, or 3,000 subjects for 30 years to prevent one fatal heart attack. The risk of dying from complications of ASA over 90,000 patient years exceeds 1!
Conventional risk factors have been shown to be entirely too weak and unreliable to base therapy decisions upon, especially when these interventions have risks. Primum non nocere
I agree 100% to to your idea - Prumum non nocere